OncoMatch/Clinical Trials/NCT04787289
A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer
Is NCT04787289 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Bevacizumab for ovarian cancer.
Treatment: Bevacizumab — A pragmatic, two armed, study comparing 2 standard doses of an anti-cancer drug called bevacizumab, given in combination with Chemotherapy. The study will be offered to ovarian cancer patients whose disease is platinum chemotherapy resistant . Higher doses of anti-cancer based drugs are not always better than lower doses and can cause more side effects without improvement of cancer. These patients will be randomly assigned either 7.5 mg/kg or 15mg/kg of bevacizumab combined with chemotherapy . Comparing these two doses will determine if the lower dose-level is non-inferior, and could lead to practice changes.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Ovarian Cancer
Disease stage
Required: Stage IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
all patients must have received at least one prior regimen of chemotherapy including platinum
Cannot have received: anti-angiogenesis inhibitor (bevacizumab)
Patients must have never received an anti-angiogenesis inhibitor including bevacizumab
Lab requirements
Blood counts
Neutrophils less than 1 x 10^9 /L [excluded]
Neutrophils less than 1 x 10^9 /L [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04787289 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-angiogenesis inhibitor disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages